Topics of Interest: Alzheimer's
Questions and answers on launch of NIA memory impairment study
March 15, 1999
1. What is Mild Cognitive Impairment? Mild cognitive impairment (MCI) is a condition characterized by memory impairment with otherwise unaffected cognitive functioning. 2. How can MCI be distinguished from normal forgetfulness? Normal...
NIA launches national study to treat mild cognitive impairment
March 15, 1999
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. The start-up of the trial,...
Scientists discover new gene associated with Alzheimer's
February 27, 1998
University of Pittsburgh researchers supported by the National Institute on Aging (NIA) and the National Cancer Institute report in the March 1998 issue of Nature Genetics the discovery of a new genetic association with Alzheimer's...
26 National Alzheimer's Disease Centers collaborate on study of the utility of genetic testing for Alzheimer's
February 18, 1998
Scientists at 26 Alzheimer's Disease Centers have collaborated on a study that concludes that a test for a form of an Alzheimer's-related gene, called ApoE, when administered after an initial clinical evaluation, reduces the number...
16-year study is further evidence that estrogen replacement may be protective against Alzheimer's disease
June 18, 1997
Scientists at the National Institute on Aging (NIA) and Johns Hopkins Bayview Medical Center have shown that a history of estrogen replacement therapy (ERT) in women after menopause was associated with a reduction, by over 50 percent, in...
New study finds substance that helps working memory work better
June 9, 1997
The drug, physostigmine, when administered to people by infusion in laboratory tests, aids and improves performance of everyday working memory. Working memory is the process which temporarily holds information such as a phone number until...
New drug therapies delay effects of Alzheimer's disease
April 23, 1997
Selegiline (or Eldepryl) and alpha-tocopherol (or Vitamin E) may slow important functional signs and symptoms of Alzheimer's disease by about 7 months, according to a report by scientists at 23 Alzheimer's Disease Cooperative Study...
New findings on Alzheimer's disease offer clues on causes, diagnosis, and treatments
March 11, 1997
Research on Alzheimer's disease is entering a new, highly productive phase and the pace of promising developments is accelerating, according to scientists at the National Institute on Aging (NIA). In an editorial examining important...
Anti-inflammatory drugs may help reduce risk of Alzheimer's disease
March 10, 1997
In a 15-year study, anti-inflammatory drugs such as ibuprofen, taken for as little as two years, appear to reduce the risk of Alzheimer's Disease (AD). Acetaminophen, with no anti-inflammatory activity, had no effect on the risk of AD...
Estrogen and delayed onset of Alzheimer's disease
August 16, 1996
National Institute on Aging (NIA)-supported scientists at Columbia-Presbyterian Medical Center suggest that estrogen therapy taken by post-menopausal women may significantly delay the onset of Alzheimer's disease. Results of the study...